Exact Sciences (EXAS) Financials

$56.95 +0.47 (+0.83%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$56.04 -0.92 (-1.61%)

As of 05/23/2025 07:00 PM Eastern

Annual Income Statements for Exact Sciences

This table shows Exact Sciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	-1,029	-204	-624	-596	-824	-213	-175	-114	-167	-158
Consolidated Net Income / (Loss)	-1,029	-204	-624	-596	-824	-213	-175	-114	-167	-158
Net Income / (Loss) Continuing Operations	-1,029	-204	-624	-596	-824	-213	-175	-114	-167	-158
Total Pre-Tax Income	-1,036	-202	-633	-843	-829	-406	-175	-115	-167	-158
Total Operating Income	-1,049	-215	-594	-856	-768	-234	-159	-118	-169	-159
Total Gross Profit	1,919	1,762	1,423	1,308	1,137	660	338	188	54	15
Total Revenue	2,759	2,500	2,084	1,767	1,491	876	454	266	99	39
Operating Revenue	2,759	2,500	2,084	1,767	1,491	876	454	266	99	39
Total Cost of Revenue	840	738	661	459	354	217	117	78	45	25
Operating Cost of Revenue	840	738	661	459	354	217	117	78	45	25
Total Operating Expenses	2,967	1,977	2,016	2,164	1,905	893	497	306	223	174
Selling, General & Admin Expense	782	800	663	801	481	352	178	109	77	58
Marketing Expense	894	828	930	862	590	385	249	154	113	82
Research & Development Expense	431	427	394	386	554	140	67	42	33	34
Other Operating Expenses / (Income)	-9.20	-78	13	0.00	-24	0.00	0.00	-	-	-
Impairment Charge	869	0.62	16	20	210	0.00	0.00	-	-	-
Total Other Income / (Expense), net	13	13	-39	13	-61	-173	-16	3.73	1.81	1.27
Interest Expense	27	19	20	19	68	199	37	0.21	0.21	0.01
Other Income / (Expense), net	40	-	-19	32	6.57	-	-	-	-	-
Income Tax Expense	-7.30	2.40	-9.06	-247	-5.46	-193	0.09	-0.19	-	-
Basic Earnings per Share	($5.59)	($1.13)	($3.54)	($3.48)	($5.45)	($1.62)	($1.43)	($0.99)	($1.63)	($1.71)
Weighted Average Basic Shares Outstanding	184.20M	180.14M	176.35M	171.35M	151.14M	131.26M	122.21M	115.68M	102.34M	92.14M
Diluted Earnings per Share	($5.59)	($1.13)	($3.54)	($3.48)	($5.45)	($1.62)	($1.43)	($0.99)	($1.63)	($1.71)
Weighted Average Diluted Shares Outstanding	184.20M	180.14M	176.35M	171.35M	151.14M	131.26M	122.21M	115.68M	102.34M	92.14M
Weighted Average Basic & Diluted Shares Outstanding	185.76M	181.53M	-	178.22M	151.14M	131.26M	122.21M	115.68M	102.34M	92.14M

This table shows Exact Sciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-101	-865	-38	-16	-110	-50	0.79	-81	-74	-128	-149
Consolidated Net Income / (Loss)	-101	-865	-38	-16	-110	-50	0.79	-81	-74	-128	-149
Net Income / (Loss) Continuing Operations	-101	-865	-38	-16	-110	-50	0.79	-81	-74	-128	-149
Total Pre-Tax Income	-101	-876	-37	-14	-108	-50	1.04	-80	-72	-130	-152
Total Operating Income	-96	-876	-39	-26	-107	-68	6.85	-77	-77	-119	-138
Total Gross Profit	501	429	513	509	467	392	460	465	446	319	375
Total Revenue	707	713	709	699	638	647	628	622	602	553	523
Operating Revenue	707	713	709	699	638	647	628	622	602	553	523
Total Cost of Revenue	206	284	196	190	170	255	169	157	157	234	148
Operating Cost of Revenue	206	284	196	190	170	255	169	157	157	234	148
Total Operating Expenses	597	1,306	552	536	574	460	453	542	523	438	513
Selling, General & Admin Expense	221	120	217	202	243	128	217	238	217	120	192
Marketing Expense	264	322	195	185	192	291	173	176	187	294	188
Research & Development Expense	105	100	100	121	111	116	111	104	95	95	91
Other Operating Expenses / (Income)	0.00	-2.57	-3.10	-3.80	0.27	-6.40	-72	0.00	0.00	-	13
Impairment Charge	6.25	838	19	8.15	4.45	-	0.00	0.55	0.07	3.43	5.95
Total Other Income / (Expense), net	-4.98	0.39	1.98	12	-1.73	17	-5.81	-2.99	4.60	-11	-14
Interest Expense	9.98	9.58	9.61	-0.11	7.94	7.87	7.87	7.82	-4.11	5.41	5.24
Other Income / (Expense), net	5.00	-	-	-	6.21	-	-	-	-	-5.64	-8.58
Income Tax Expense	0.22	-11	0.81	1.46	1.81	-0.61	0.25	1.11	1.66	-2.18	-3.12
Basic Earnings per Share	($0.54)	($4.69)	($0.21)	($0.09)	($0.60)	($0.26)	$0.00	($0.45)	($0.42)	($0.72)	($0.84)
Weighted Average Basic Shares Outstanding	186.81M	184.20M	184.80M	184.31M	182.35M	180.14M	180.65M	180.20M	178.57M	176.35M	177.00M
Diluted Earnings per Share	($0.54)	-	($0.21)	($0.09)	-	-	$0.00	($0.45)	-	($0.72)	($0.84)
Weighted Average Diluted Shares Outstanding	186.81M	184.20M	184.80M	184.31M	184.53M	180.14M	184.08M	180.20M	180.85M	176.35M	177.00M
Weighted Average Basic & Diluted Shares Outstanding	188.64M	185.76M	185.08M	184.77M	184.53M	181.53M	-	-	180.85M	0.00	177.68M

This table details how cash moves in and out of Exact Sciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	-3.04	367	-73	-1,176	1,314	17	83	29	7.79	-17
Net Cash From Operating Activities	211	156	-224	-102	136	-112	-69	-72	-130	-134
Net Cash From Continuing Operating Activities	211	156	-224	-102	136	-112	-69	-72	-130	-134
Net Income / (Loss) Continuing Operations	-1,029	-204	-624	-596	-824	-213	-175	-114	-167	-158
Consolidated Net Income / (Loss)	-1,029	-204	-624	-596	-824	-213	-175	-114	-167	-158
Depreciation Expense	120	114	100	85	70	34	21	15	11	7.60
Amortization Expense	95	92	97	95	96	14	29	-0.55	-0.30	0.94
Non-Cash Adjustments To Reconcile Net Income	1,094	173	297	449	843	300	58	36	25	17
Changes in Operating Assets and Liabilities, net	-69	-19	-95	-136	-49	-247	-0.91	-7.79	1.45	-1.85
Net Cash From Investing Activities	-442	50	74	-1,082	-702	-124	-782	-161	-12	-65
Net Cash From Continuing Investing Activities	-442	50	74	-1,082	-702	-124	-782	-161	-12	-65
Purchase of Property, Plant & Equipment	-181	-125	-214	-194	-476	-173	-150	-48	-15	-20
Acquisitions	0.00	-52	-15	-500	-6.66	-974	-18	-24	-	-1.90
Purchase of Investments	-467	-156	-174	-1,182	-1,106	-634	-1,193	-357	-190	-205
Sale of Property, Plant & Equipment	0.00	0.00	25	0.00	0.00	-	-	-	-	-
Sale and/or Maturity of Investments	206	383	453	794	887	1,657	579	271	193	162
Other Investing Activities, net	-0.23	0.25	-0.55	-0.74	0.35	-1.00	-0.58	-3.07	-	-
Net Cash From Financing Activities	232	160	76	8.47	1,880	253	934	261	150	182
Net Cash From Continuing Financing Activities	232	160	76	8.47	1,880	253	934	261	150	182
Repayment of Debt	-68	0.00	0.00	-29	-151	-493	0.00	-0.20	-	-
Issuance of Debt	267	128	44	0.00	1,124	729	923	0.00	-	5.47
Issuance of Common Equity	33	32	32	38	907	17	12	261	150	177
Effect of Exchange Rate Changes	-3.29	1.32	0.03	0.02	0.00	0.00	-	-	-0.22	0.01
Cash Interest Paid	28	19	12	11	9.38	5.13	4.64	0.20	0.21	0.10

This table details how cash moves in and out of Exact Sciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-260	12	59	184	-258	15	-9.75	183	179	7.19	22
Net Cash From Operating Activities	31	47	139	107	-82	70	24	100	-38	52	-41
Net Cash From Continuing Operating Activities	31	47	139	107	-82	70	24	100	-38	52	-41
Net Income / (Loss) Continuing Operations	-101	-865	-38	-16	-110	-50	0.79	-81	-74	-128	-149
Consolidated Net Income / (Loss)	-101	-865	-38	-16	-110	-50	0.79	-81	-74	-128	-149
Depreciation Expense	30	29	30	30	31	31	29	28	27	27	25
Amortization Expense	24	24	24	23	23	23	23	23	23	23	24
Non-Cash Adjustments To Reconcile Net Income	73	893	73	53	75	44	5.20	73	51	63	89
Changes in Operating Assets and Liabilities, net	5.44	-34	49	16	-101	21	-34	58	-65	67	-30
Net Cash From Investing Activities	-34	-42	-82	-147	-171	-67	-33	66	83	-58	65
Net Cash From Continuing Investing Activities	-34	-42	-82	-147	-171	-67	-33	66	83	-58	66
Purchase of Property, Plant & Equipment	-31	-81	-26	-36	-38	-35	-25	-35	-29	-73	-45
Purchase of Investments	-80	-60	-81	-148	-178	-75	-25	-48	-9.03	-45	-23
Sale and/or Maturity of Investments	78	55	71	36	44	46	67	149	121	76	108
Other Investing Activities, net	-0.51	-	-0.02	-	-0.21	0.50	0.25	-0.50	0.00	-0.50	-
Net Cash From Financing Activities	-256	10	-0.23	225	-3.00	10	0.09	16	134	10	0.24
Net Cash From Continuing Financing Activities	-256	10	-0.23	225	-3.00	10	0.09	16	134	10	0.24
Repayment of Debt	-249	-18	-	-48	-1.59	-	6.50	-1.16	-5.34	5.11	-0.71
Issuance of Debt	-6.58	16	-2.36	254	0.00	-2.27	-7.48	-	138	-5.53	-
Other Financing Activities, net	-0.42	-	2.13	0.04	-1.41	-	1.08	0.85	0.96	-	-
Other Net Changes in Cash	0.29	-	-	-	-	-	-	-	-	-	-
Cash Interest Paid	9.47	6.73	9.14	1.18	11	0.60	11	0.94	6.44	0.77	5.62

This table presents Exact Sciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2022	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	5,928	6,471	6,227	6,227	4,925	3,506	1,524	599	377	364
Total Current Assets	1,571	1,194	982	982	2,199	554	1,228	487	334	326
Cash & Equivalents	601	605	242	242	1,491	177	160	77	49	41
Short-Term Investments	437	172	390	390	349	146	964	347	262	266
Accounts Receivable	249	204	158	158	233	130	45	26	8.53	4.93
Inventories, net	162	127	118	118	92	62	39	26	6.83	6.68
Prepaid Expenses	122	86	74	74	33	38	19	10	7.11	7.38
Plant, Property, & Equipment, net	694	698	685	685	452	455	245	80	38	34
Total Noncurrent Assets	3,663	4,579	4,560	4,560	2,275	2,497	51	31	5.33	4.07
Goodwill	2,367	2,367	2,346	2,346	1,238	1,203	17	24	-	-
Intangible Assets	1,010	1,890	1,956	1,956	847	1,144	29	-	1.55	-
Other Noncurrent Operating Assets	287	321	258	258	190	150	4.42	7.15	3.78	4.07
Total Liabilities & Shareholders' Equity	5,928	6,471	6,227	6,227	4,925	3,506	1,524	599	377	364
Total Liabilities	3,526	3,326	3,184	3,184	2,690	1,218	843	78	42	37
Total Current Liabilities	732	515	413	413	633	236	136	68	31	27
Short-Term Debt	249	50	0.00	-	314	0.83	0.01	0.18	0.17	0.17
Accounts Payable	90	79	75	75	36	26	28	16	0.71	3.31
Accrued Expenses	328	342	299	299	234	193	101	49	28	22
Other Current Liabilities	65	44	39	39	50	16	7.38	2.68	1.70	1.00
Total Noncurrent Liabilities	2,794	2,811	2,771	2,771	2,056	981	707	10	11	10
Long-Term Debt	2,321	2,314	2,236	2,236	1,884	828	689	4.27	4.63	4.79
Capital Lease Obligations	157	161	182	182	121	119	-	-	0.69	1.06
Other Noncurrent Operating Liabilities	316	336	352	352	51	35	18	5.75	5.73	4.60
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	2,402	3,145	3,043	3,043	2,236	2,288	681	520	335	327
Total Preferred & Common Equity	2,402	3,145	3,043	3,043	2,236	2,288	681	520	335	327
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	2,402	3,145	3,043	3,043	2,236	2,288	681	520	335	327
Common Stock	6,901	6,613	6,313	6,313	4,281	3,408	1,718	1,382	1,082	906
Retained Earnings	-4,498	-3,469	-3,265	-3,265	-2,046	-1,120	-1,036	-861	-746	-579
Accumulated Other Comprehensive Income / (Loss)	-0.94	1.43	-5.24	-5.24	0.53	-0.10	-1.42	-0.75	-0.42	-0.43

This table presents Exact Sciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	12/31/2022
Total Assets	5,711	6,749	6,673	6,376	6,421	6,227
Total Current Assets	1,370	1,533	1,452	1,120	1,148	982
Cash & Equivalents	347	589	530	347	595	242
Short-Term Investments	439	432	417	305	140	390
Accounts Receivable	280	265	264	241	199	158
Inventories, net	177	137	127	129	133	118
Prepaid Expenses	128	110	114	99	82	74
Plant, Property, & Equipment, net	698	690	703	702	692	685
Total Noncurrent Assets	3,643	4,525	4,518	4,554	4,580	4,560
Goodwill	2,367	2,367	2,367	2,367	2,367	2,346
Intangible Assets	989	1,864	1,843	1,867	1,913	1,956
Other Noncurrent Operating Assets	287	293	307	320	300	258
Total Liabilities & Shareholders' Equity	5,711	6,749	6,673	6,376	6,421	6,227
Total Liabilities	3,314	3,538	3,481	3,244	3,300	3,184
Total Current Liabilities	502	724	669	685	477	413
Short-Term Debt	0.00	249	249	299	50	0.00
Accounts Payable	142	98	53	60	74	75
Accrued Expenses	295	314	303	265	310	299
Other Current Liabilities	65	63	64	61	43	39
Total Noncurrent Liabilities	2,812	2,814	2,812	2,559	2,823	2,771
Long-Term Debt	2,323	2,319	2,318	2,067	2,313	2,236
Capital Lease Obligations	169	163	168	162	168	182
Other Noncurrent Operating Liabilities	320	332	327	329	342	352
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	2,397	3,211	3,192	3,133	3,121	3,043
Total Preferred & Common Equity	2,397	3,211	3,192	3,133	3,121	3,043
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	2,397	3,211	3,192	3,133	3,121	3,043
Common Stock	6,995	6,839	6,789	6,713	6,542	6,313
Retained Earnings	-4,599	-3,633	-3,595	-3,579	-3,419	-3,265
Accumulated Other Comprehensive Income / (Loss)	1.01	4.63	-0.94	-0.50	-1.54	-5.24

This table displays calculated financial ratios and metrics derived from Exact Sciences' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	10.37%	19.93%	17.95%	18.49%	70.19%	92.82%	70.86%	167.66%	151.99%	2,093.38%
EBITDA Growth	-9,351.29%	97.98%	35.46%	-8.22%	-220.93%	-68.12%	-5.69%	34.00%	-4.97%	-56.34%
EBIT Growth	-369.34%	64.92%	25.61%	-8.25%	-225.57%	-46.60%	-34.79%	30.00%	-6.25%	-58.22%
NOPAT Growth	-387.74%	63.77%	30.64%	-11.46%	-228.38%	-46.60%	-34.79%	30.00%	-6.25%	-58.22%
Net Income Growth	-403.97%	67.26%	-4.68%	27.68%	-286.51%	-21.66%	-53.11%	31.59%	-5.96%	-57.73%
EPS Growth	-394.69%	68.08%	-1.72%	36.15%	-236.42%	-13.29%	-44.44%	39.26%	4.68%	-36.80%
Operating Cash Flow Growth	34.86%	169.83%	-118.67%	-174.91%	222.24%	-61.96%	3.88%	44.86%	2.95%	-64.52%
Free Cash Flow Firm Growth	131.48%	48.51%	84.69%	-696.92%	87.96%	-998.77%	-67.98%	-25.64%	4.71%	-73.68%
Invested Capital Growth	-16.38%	1.31%	0.00%	77.91%	-6.76%	1,083.51%	145.63%	237.36%	14.22%	179.25%
Revenue Q/Q Growth	2.47%	3.90%	3.95%	0.42%	12.93%	21.09%	13.93%	24.40%	26.51%	48.70%
EBITDA Q/Q Growth	-3,167.46%	86.90%	18.73%	25.54%	-84.86%	-49.73%	-13.77%	13.16%	1.93%	-4.68%
EBIT Q/Q Growth	-320.14%	19.18%	11.94%	21.47%	-69.59%	-25.01%	-19.77%	11.07%	1.58%	-5.18%
NOPAT Q/Q Growth	-336.61%	19.18%	14.74%	18.45%	-71.06%	-25.01%	-19.77%	11.07%	1.58%	-5.18%
Net Income Q/Q Growth	-380.69%	27.64%	12.96%	24.92%	-80.46%	1.32%	-22.53%	11.87%	1.66%	-5.02%
EPS Q/Q Growth	0.00%	0.00%	14.08%	29.27%	-78.10%	4.71%	-22.22%	13.16%	5.78%	-1.79%
Operating Cash Flow Q/Q Growth	-9.65%	12.63%	25.52%	-403.01%	61,302.69%	-28.04%	-0.13%	26.88%	2.37%	0.87%
Free Cash Flow Firm Q/Q Growth	101.32%	-104.61%	41.75%	-0.33%	86.60%	-757.30%	-11.71%	-15.71%	4.43%	-5.49%
Invested Capital Q/Q Growth	-16.85%	0.00%	0.00%	4.91%	3.10%	617.25%	18.94%	44.03%	-1.64%	14.35%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	69.55%	70.49%	68.27%	74.04%	76.24%	75.27%	74.33%	70.56%	54.52%	37.87%
EBITDA Margin	-28.79%	-0.34%	-19.93%	-36.42%	-39.87%	-21.15%	-24.25%	-39.21%	-159.00%	-381.68%
Operating Margin	-38.01%	-8.60%	-28.48%	-48.42%	-51.48%	-26.68%	-35.09%	-44.48%	-170.08%	-403.35%
EBIT Margin	-36.58%	-8.60%	-29.41%	-46.62%	-51.03%	-26.68%	-35.09%	-44.48%	-170.08%	-403.35%
Profit (Net Income) Margin	-37.29%	-8.17%	-29.91%	-33.71%	-55.22%	-24.32%	-38.54%	-43.01%	-168.26%	-400.14%
Tax Burden Percent	99.30%	101.19%	98.57%	70.70%	99.34%	52.43%	100.05%	99.84%	100.00%	100.00%
Interest Burden Percent	102.68%	93.83%	103.20%	102.26%	108.93%	173.86%	109.77%	96.85%	98.93%	99.20%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-16.34%	-3.10%	-8.60%	-15.88%	-19.10%	-10.37%	-64.50%	-127.57%	-424.96%	-630.85%
ROIC Less NNEP Spread (ROIC-NNEP)	-33.49%	-6.13%	-20.25%	-15.58%	-71.02%	-62.81%	-49.64%	-118.86%	-408.83%	-614.84%
Return on Net Nonoperating Assets (RNNOA)	-20.75%	-3.50%	-11.89%	-6.69%	-17.31%	-3.99%	35.34%	100.83%	374.46%	579.60%
Return on Equity (ROE)	-37.09%	-6.60%	-20.49%	-22.57%	-36.41%	-14.35%	-29.16%	-26.74%	-50.51%	-51.25%
Cash Return on Invested Capital (CROIC)	1.50%	-4.40%	-8.60%	-71.95%	-12.11%	-179.20%	-148.77%	-236.11%	-438.23%	-725.38%
Operating Return on Assets (OROA)	-16.28%	-3.39%	-9.84%	-14.78%	-18.06%	-9.30%	-15.03%	-24.25%	-45.61%	-47.00%
Return on Assets (ROA)	-16.60%	-3.22%	-10.01%	-10.68%	-19.54%	-8.47%	-16.50%	-23.45%	-45.13%	-46.63%
Return on Common Equity (ROCE)	-37.09%	-6.60%	-20.49%	-22.57%	-36.41%	-14.35%	-29.16%	-26.74%	-50.51%	-51.25%
Return on Equity Simple (ROE_SIMPLE)	-42.83%	-6.49%	-20.49%	-19.57%	-36.84%	-9.31%	-25.72%	-21.98%	-49.87%	-48.28%
Net Operating Profit after Tax (NOPAT)	-734	-151	-415	-599	-537	-164	-112	-83	-118	-111
NOPAT Margin	-26.61%	-6.02%	-19.93%	-33.90%	-36.03%	-18.68%	-24.56%	-31.14%	-119.05%	-282.34%
Net Nonoperating Expense Percent (NNEP)	17.15%	3.04%	11.65%	-0.30%	51.92%	52.45%	-14.85%	-8.70%	-16.13%	-16.00%
Return On Investment Capital (ROIC_SIMPLE)	-14.31%	-2.65%	-7.61%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	30.45%	29.51%	31.73%	25.96%	23.76%	24.73%	25.67%	29.44%	45.48%	62.13%
SG&A Expenses to Revenue	28.34%	32.01%	31.83%	45.34%	32.28%	40.22%	39.17%	40.97%	77.38%	146.94%
R&D to Revenue	15.63%	17.08%	18.91%	21.82%	37.15%	15.94%	14.81%	15.83%	33.68%	86.00%
Operating Expenses to Revenue	107.56%	79.10%	96.74%	122.46%	127.72%	101.95%	109.42%	115.04%	224.60%	441.22%
Earnings before Interest and Taxes (EBIT)	-1,009	-215	-613	-824	-761	-234	-159	-118	-169	-159
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-794	-8.40	-415	-644	-595	-185	-110	-104	-158	-151
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.33	4.25	2.89	4.41	8.91	5.25	11.39	12.09	4.32	2.72
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	132.20	0.00	12.22	12.68	4.34	2.72
Price to Revenue (P/Rev)	3.77	5.35	4.22	7.59	13.36	13.70	17.06	23.65	14.57	22.55
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.95	3.09	2.19	3.15	7.52	4.34	29.76	58.61	38.49	22.63
Enterprise Value to Revenue (EV/Rev)	4.38	6.05	5.08	8.60	13.68	14.41	16.11	22.07	11.50	14.92
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	57.42	96.89	0.00	0.00	149.54	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	179.52	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.14	0.80	0.79	0.79	1.04	0.41	1.01	0.01	0.02	0.02
Long-Term Debt to Equity	1.03	0.79	0.79	0.79	0.90	0.41	1.01	0.01	0.02	0.02
Financial Leverage	0.62	0.57	0.59	0.43	0.24	0.06	-0.71	-0.85	-0.92	-0.94
Leverage Ratio	2.24	2.05	2.05	2.11	1.86	1.69	1.77	1.14	1.12	1.10
Compound Leverage Factor	2.30	1.93	2.11	2.16	2.03	2.95	1.94	1.10	1.11	1.09
Debt to Total Capital	53.17%	44.53%	44.28%	44.28%	50.92%	29.28%	50.30%	0.85%	1.61%	1.81%
Short-Term Debt to Total Capital	4.86%	0.88%	0.00%	0.00%	6.89%	0.03%	0.00%	0.03%	0.05%	0.05%
Long-Term Debt to Total Capital	48.31%	43.65%	44.28%	44.28%	44.02%	29.25%	50.30%	0.81%	1.56%	1.76%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	46.83%	55.47%	55.72%	55.72%	49.08%	70.72%	49.70%	99.15%	98.39%	98.19%
Debt to EBITDA	-3.43	-300.49	-5.82	-3.76	-3.90	-5.11	-6.25	-0.04	-0.03	-0.04
Net Debt to EBITDA	-2.13	-207.96	-4.30	-2.78	-0.81	-3.36	3.95	4.03	1.93	2.00
Long-Term Debt to EBITDA	-3.12	-294.54	-5.82	-3.76	-3.37	-5.11	-6.25	-0.04	-0.03	-0.04
Debt to NOPAT	-3.72	-16.78	-5.82	-4.04	-4.32	-5.79	-6.17	-0.05	-0.05	-0.05
Net Debt to NOPAT	-2.30	-11.61	-4.30	-2.98	-0.89	-3.81	3.90	5.07	2.58	2.70
Long-Term Debt to NOPAT	-3.38	-16.45	-5.82	-4.04	-3.73	-5.78	-6.17	-0.05	-0.05	-0.05
Altman Z-Score	0.78	2.07	1.04	1.75	4.04	5.61	5.38	46.92	17.80	11.78
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.15	2.32	2.38	2.38	3.47	2.34	9.02	7.15	10.87	12.19
Quick Ratio	1.76	1.91	1.91	1.91	3.27	1.92	8.59	6.62	10.41	11.67
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	67	-214	-415	-2,714	-341	-2,829	-257	-153	-122	-128
Operating Cash Flow to CapEx	116.33%	125.21%	-118.00%	-52.74%	28.64%	-64.67%	-45.93%	-147.95%	-875.81%	-667.28%
Free Cash Flow to Firm to Interest Expense	2.49	-11.00	-21.16	-145.86	-5.01	-14.20	-7.00	-744.09	-572.80	-21,338.77
Operating Cash Flow to Interest Expense	7.79	8.03	-11.39	-5.49	2.01	-0.56	-1.87	-348.17	-610.64	-22,336.17
Operating Cash Flow Less CapEx to Interest Expense	1.09	1.62	-21.04	-15.91	-5.00	-1.43	-5.95	-583.51	-680.36	-25,683.50
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.45	0.39	0.33	0.32	0.35	0.35	0.43	0.55	0.27	0.12
Accounts Receivable Turnover	12.19	13.82	13.19	9.03	8.20	9.98	12.67	15.22	14.77	12.50
Inventory Turnover	5.80	6.00	5.59	4.36	4.60	4.30	3.58	4.77	6.69	4.58
Fixed Asset Turnover	3.96	3.61	3.04	3.11	3.29	2.50	2.79	4.50	2.75	1.46
Accounts Payable Turnover	9.98	9.60	8.83	8.29	11.49	8.01	5.27	9.30	22.50	8.23
Days Sales Outstanding (DSO)	29.94	26.40	27.68	40.41	44.49	36.59	28.81	23.98	24.72	29.20
Days Inventory Outstanding (DIO)	62.96	60.80	65.27	83.75	79.31	84.95	101.97	76.58	54.55	79.66
Days Payable Outstanding (DPO)	36.58	38.04	41.35	44.01	31.77	45.57	69.27	39.26	16.22	44.36
Cash Conversion Cycle (CCC)	56.33	49.17	51.60	80.15	92.03	75.97	61.51	61.30	63.05	64.50
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	4,092	4,893	4,830	4,830	2,715	2,912	246	100	30	26
Invested Capital Turnover	0.61	0.51	0.43	0.47	0.53	0.56	2.63	4.10	3.57	2.23
Increase / (Decrease) in Invested Capital	-801	63	0.00	2,115	-197	2,666	146	70	3.70	17
Enterprise Value (EV)	12,089	15,127	10,584	15,198	20,409	12,630	7,320	5,870	1,143	588
Market Capitalization	10,399	13,379	8,797	13,412	19,930	12,007	7,755	6,291	1,448	889
Book Value per Share	$12.98	$17.39	$17.13	$17.66	$14.86	$17.62	$5.54	$4.35	$3.09	$3.39
Tangible Book Value per Share	($5.26)	($6.15)	($7.09)	($7.31)	$1.00	($0.45)	$5.16	$4.14	$3.08	$3.39
Total Capital	5,130	5,671	5,462	5,462	4,555	3,235	1,370	525	341	333
Total Debt	2,727	2,525	2,419	2,419	2,319	947	689	4.45	5.49	6.02
Total Long-Term Debt	2,478	2,475	2,419	2,419	2,005	946	689	4.27	5.32	5.85
Net Debt	1,689	1,748	1,786	1,786	479	623	-435	-420	-306	-301
Capital Expenditures (CapEx)	181	125	189	194	476	173	150	48	15	20
Debt-free, Cash-free Net Working Capital (DFCFNWC)	50	-48	-63	-63	40	-5.38	-32	-5.44	-8.05	-7.57
Debt-free Net Working Capital (DFNWC)	1,088	730	570	570	1,880	318	1,092	419	303	299
Net Working Capital (NWC)	839	680	570	570	1,565	317	1,092	419	303	299
Net Nonoperating Expense (NNE)	295	54	208	-3.35	286	49	64	32	49	46
Net Nonoperating Obligations (NNO)	1,689	1,748	1,786	1,786	479	623	-435	-420	-306	-301
Total Depreciation and Amortization (D&A)	215	207	198	180	166	48	49	14	11	8.54
Debt-free, Cash-free Net Working Capital to Revenue	1.83%	-1.92%	-3.00%	-3.54%	2.65%	-0.61%	-7.10%	-2.05%	-8.10%	-19.20%
Debt-free Net Working Capital to Revenue	39.45%	29.19%	27.32%	32.23%	126.03%	36.32%	240.26%	157.63%	304.96%	758.95%
Net Working Capital to Revenue	30.42%	27.19%	27.32%	32.23%	104.97%	36.23%	240.26%	157.56%	304.78%	758.53%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($5.59)	($1.13)	$0.00	$0.00	($5.61)	($0.64)	($1.43)	($0.99)	($1.63)	($1.71)
Adjusted Weighted Average Basic Shares Outstanding	184.20M	180.14M	0.00	0.00	169.09M	443.90M	125.76M	120.94M	110.60M	97.45M
Adjusted Diluted Earnings per Share	($5.59)	($1.13)	$0.00	$0.00	($5.61)	($0.64)	($1.43)	($0.99)	($1.63)	($1.71)
Adjusted Weighted Average Diluted Shares Outstanding	184.20M	180.14M	0.00	0.00	169.09M	443.90M	125.76M	120.94M	110.60M	97.45M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	($5.61)	($0.64)	($1.43)	($0.99)	($1.63)	($1.71)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	185.76M	181.53M	0.00	0.00	151.14M	131.26M	122.21M	115.68M	102.34M	92.14M
Normalized Net Operating Profit after Tax (NOPAT)	-125	-150	-404	-585	-391	-164	-112	-83	-118	-111
Normalized NOPAT Margin	-4.55%	-6.00%	-19.40%	-33.10%	-26.19%	-18.68%	-24.56%	-31.14%	-119.05%	-282.34%
Pre Tax Income Margin	-37.56%	-8.07%	-30.35%	-47.68%	-55.59%	-46.38%	-38.52%	-43.08%	-168.26%	-400.14%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-37.35	-11.06	-31.22	-44.28	-11.20	-1.17	-4.33	-574.32	-793.50	-26,511.33
NOPAT to Interest Expense	-27.17	-7.74	-21.16	-32.19	-7.91	-0.82	-3.03	-402.02	-555.45	-18,557.93
EBIT Less CapEx to Interest Expense	-44.05	-17.47	-40.87	-54.70	-18.22	-2.04	-8.41	-809.66	-863.23	-29,858.67
NOPAT Less CapEx to Interest Expense	-33.87	-14.15	-30.81	-42.61	-14.92	-1.69	-7.11	-637.36	-625.17	-21,905.27
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Exact Sciences' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	10.86%	10.29%	12.78%	12.41%	5.82%	16.98%	20.12%	19.26%	23.82%	16.71%	14.61%
EBITDA Growth	20.59%	-5,922.42%	-74.00%	200.95%	-70.16%	81.78%	160.26%	76.59%	78.82%	59.34%	12.83%
EBIT Growth	9.42%	-1,191.77%	-675.31%	65.87%	-30.34%	45.52%	104.67%	52.89%	56.81%	43.77%	9.49%
NOPAT Growth	10.01%	-1,191.77%	-629.01%	65.87%	-38.40%	42.93%	105.40%	51.79%	56.44%	46.32%	14.79%
Net Income Growth	8.18%	-1,637.30%	-4,915.62%	80.49%	-48.65%	61.04%	100.53%	51.21%	59.02%	42.09%	10.89%
EPS Growth	10.00%	0.00%	0.00%	80.00%	0.00%	0.00%	100.00%	52.13%	0.00%	44.62%	13.40%
Operating Cash Flow Growth	137.43%	-32.33%	469.43%	6.61%	-115.39%	33.65%	159.52%	264.86%	78.01%	311.77%	-0.37%
Free Cash Flow Firm Growth	608.29%	269.53%	-202.34%	-204.66%	2.06%	-33.25%	1,598.38%	1,075.71%	63.13%	96.33%	84.52%
Invested Capital Growth	-18.10%	-16.38%	0.00%	0.00%	1.84%	1.31%	0.00%	0.00%	2.39%	0.00%	4.91%
Revenue Q/Q Growth	-0.93%	0.67%	1.34%	9.68%	0.00%	2.95%	1.00%	3.26%	8.94%	5.72%	0.27%
EBITDA Q/Q Growth	95.51%	-5,456.61%	-42.53%	157.46%	0.00%	-123.13%	323.11%	3.14%	63.55%	23.49%	13.32%
EBIT Q/Q Growth	89.61%	-2,124.07%	-50.07%	73.87%	0.00%	-1,090.52%	108.90%	0.21%	38.09%	15.09%	10.20%
NOPAT Q/Q Growth	89.04%	-2,124.07%	-50.07%	75.39%	0.00%	-1,010.81%	109.68%	0.21%	35.15%	13.89%	13.49%
Net Income Q/Q Growth	88.29%	-2,161.18%	-141.88%	85.66%	0.00%	-6,367.76%	100.98%	-9.27%	41.95%	14.13%	10.42%
EPS Q/Q Growth	0.00%	0.00%	-133.33%	0.00%	0.00%	0.00%	100.00%	0.00%	0.00%	14.29%	10.64%
Operating Cash Flow Q/Q Growth	-34.54%	-66.07%	29.57%	230.07%	0.00%	185.49%	-75.74%	362.79%	-173.44%	227.15%	32.82%
Free Cash Flow Firm Q/Q Growth	346.38%	103.80%	1.01%	-2,927.75%	0.00%	-102.29%	1.24%	2,933.26%	-102.55%	74.21%	34.08%
Invested Capital Q/Q Growth	0.26%	-16.85%	-1.20%	-0.57%	0.00%	0.00%	0.00%	-100.00%	1.83%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	70.82%	60.17%	72.33%	72.85%	73.32%	60.55%	73.18%	74.76%	73.96%	57.66%	71.72%
EBITDA Margin	-5.23%	-115.39%	2.17%	3.82%	-7.30%	-2.11%	9.41%	-4.26%	-4.54%	-13.57%	-18.75%
Operating Margin	-13.58%	-122.84%	-5.56%	-3.75%	-16.74%	-10.49%	1.09%	-12.37%	-12.80%	-21.50%	-26.39%
EBIT Margin	-12.88%	-122.84%	-5.56%	-3.75%	-15.76%	-10.49%	1.09%	-12.37%	-12.80%	-22.52%	-28.03%
Profit (Net Income) Margin	-14.32%	-121.19%	-5.40%	-2.26%	-17.29%	-7.69%	0.13%	-13.02%	-12.31%	-23.10%	-28.44%
Tax Burden Percent	100.22%	98.70%	102.16%	110.20%	101.67%	98.79%	76.13%	101.39%	102.29%	98.32%	97.95%
Interest Burden Percent	110.96%	99.96%	94.99%	54.63%	107.91%	74.26%	15.23%	103.89%	94.04%	104.34%	103.57%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	23.87%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-5.90%	-52.81%	-4.26%	-2.76%	-5.98%	-3.77%	0.00%	0.00%	-4.05%	-6.49%	-7.85%
ROIC Less NNEP Spread (ROIC-NNEP)	-7.80%	-67.42%	-5.51%	-2.47%	-7.92%	-3.90%	0.00%	0.00%	-5.26%	-8.99%	-11.41%
Return on Net Nonoperating Assets (RNNOA)	-5.05%	-41.77%	-2.93%	-1.38%	-4.65%	-2.23%	0.00%	0.00%	-2.76%	-5.28%	-5.15%
Return on Equity (ROE)	-10.96%	-94.58%	-7.19%	-4.14%	-10.63%	-6.00%	0.00%	0.00%	-6.81%	-11.77%	-13.00%
Cash Return on Invested Capital (CROIC)	3.95%	1.50%	-206.83%	-205.45%	-5.27%	-4.40%	0.00%	0.00%	-9.47%	-8.60%	-15.12%
Operating Return on Assets (OROA)	-6.03%	-54.66%	-2.22%	-1.47%	-6.24%	-4.13%	0.00%	0.00%	-4.36%	-7.54%	-8.73%
Return on Assets (ROA)	-6.70%	-53.93%	-2.15%	-0.88%	-6.85%	-3.03%	0.00%	0.00%	-4.19%	-7.73%	-8.85%
Return on Common Equity (ROCE)	-10.96%	-94.58%	-7.19%	-4.14%	-10.63%	-6.00%	0.00%	0.00%	-6.81%	-11.77%	-13.00%
Return on Equity Simple (ROE_SIMPLE)	-42.55%	0.00%	-6.67%	-5.48%	-7.67%	0.00%	0.00%	0.00%	-16.56%	0.00%	-23.54%
Net Operating Profit after Tax (NOPAT)	-67	-613	-28	-18	-75	-47	5.21	-54	-54	-83	-97
NOPAT Margin	-9.51%	-85.99%	-3.89%	-2.63%	-11.71%	-7.34%	0.83%	-8.66%	-8.96%	-15.05%	-18.48%
Net Nonoperating Expense Percent (NNEP)	1.90%	14.61%	1.25%	-0.29%	1.94%	0.13%	0.00%	0.00%	1.21%	2.49%	3.55%
Return On Investment Capital (ROIC_SIMPLE)	-1.37%	-11.96%	-	-	-	-0.84%	-	-	-	-1.52%	-
Cost of Revenue to Revenue	29.18%	39.83%	27.67%	27.15%	26.68%	39.45%	26.82%	25.24%	26.04%	42.34%	28.28%
SG&A Expenses to Revenue	31.22%	16.77%	30.65%	28.87%	38.13%	19.73%	34.60%	38.25%	36.07%	21.69%	36.70%
R&D to Revenue	14.90%	13.96%	14.13%	17.29%	17.35%	17.93%	17.74%	16.73%	15.84%	17.19%	17.36%
Operating Expenses to Revenue	84.40%	183.01%	77.89%	76.61%	90.05%	71.04%	72.09%	87.13%	86.76%	79.16%	98.11%
Earnings before Interest and Taxes (EBIT)	-91	-876	-39	-26	-100	-68	6.85	-77	-77	-125	-147
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-37	-823	15	27	-47	-14	59	-26	-27	-75	-98
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.35	4.33	3.92	2.44	3.99	4.25	0.00	0.00	3.87	2.89	1.89
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	2.84	3.77	4.68	2.98	4.93	5.35	5.12	7.36	5.49	4.22	2.87
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.38	2.95	2.91	1.92	2.87	3.09	0.00	0.00	2.82	2.19	1.56
Enterprise Value to Revenue (EV/Rev)	3.45	4.38	5.31	3.67	5.67	6.05	0.00	0.00	6.31	5.08	3.76
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	493.37	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	30.11	57.42	61.35	80.77	128.24	96.89	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	54.23	179.52	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.04	1.14	0.85	0.86	0.81	0.80	0.00	0.00	0.81	0.79	0.79
Long-Term Debt to Equity	1.04	1.03	0.77	0.78	0.71	0.79	0.00	0.00	0.80	0.79	0.79
Financial Leverage	0.65	0.62	0.53	0.56	0.59	0.57	0.00	0.00	0.52	0.59	0.45
Leverage Ratio	2.19	2.24	2.10	2.09	2.05	2.05	0.00	0.00	2.02	2.05	1.98
Compound Leverage Factor	2.43	2.23	2.00	1.14	2.21	1.52	0.00	0.00	1.90	2.14	2.05
Debt to Total Capital	50.97%	53.17%	45.97%	46.14%	44.66%	44.53%	0.00%	0.00%	44.78%	44.28%	44.28%
Short-Term Debt to Total Capital	0.00%	4.86%	4.19%	4.20%	5.28%	0.88%	0.00%	0.00%	0.88%	0.00%	0.00%
Long-Term Debt to Total Capital	50.97%	48.31%	41.78%	41.94%	39.38%	43.65%	0.00%	0.00%	43.90%	44.28%	44.28%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	49.03%	46.83%	54.03%	53.86%	55.34%	55.47%	0.00%	0.00%	55.22%	55.72%	55.72%
Debt to EBITDA	-3.18	-3.43	-112.35	140.77	-74.78	-300.49	0.00	0.00	-8.56	-5.82	-4.73
Net Debt to EBITDA	-2.17	-2.13	-70.35	92.03	-55.49	-207.96	0.00	0.00	-6.08	-4.30	-3.50
Long-Term Debt to EBITDA	-3.18	-3.12	-102.11	127.95	-65.94	-294.54	0.00	0.00	-8.39	-5.82	-4.73
Debt to NOPAT	-3.43	-3.72	-16.24	-20.14	-14.76	-16.78	0.00	0.00	-7.33	-5.82	-4.96
Net Debt to NOPAT	-2.35	-2.30	-10.17	-13.17	-10.96	-11.61	0.00	0.00	-5.20	-4.30	-3.67
Long-Term Debt to NOPAT	-3.43	-3.38	-14.76	-18.31	-13.02	-16.45	0.00	0.00	-7.18	-5.82	-4.96
Altman Z-Score	0.95	0.85	1.90	1.11	1.95	2.14	0.00	0.00	1.88	1.30	0.70
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.73	2.15	2.12	2.17	1.64	2.32	0.00	0.00	2.41	2.38	2.38
Quick Ratio	2.12	1.76	1.78	1.81	1.30	1.91	0.00	0.00	1.96	1.91	1.91
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	839	188	-4,948	-4,998	-165	-111	4,835	4,776	-169	-83	-323
Operating Cash Flow to CapEx	98.83%	57.88%	530.31%	298.51%	-218.63%	196.34%	96.72%	289.23%	-130.16%	71.40%	-91.69%
Free Cash Flow to Firm to Interest Expense	84.10	19.63	-515.06	0.00	-20.78	-14.10	614.26	610.87	0.00	-15.38	-61.64
Operating Cash Flow to Interest Expense	3.09	4.91	14.44	0.00	-10.36	8.84	3.10	12.85	0.00	9.62	-7.82
Operating Cash Flow Less CapEx to Interest Expense	-0.04	-3.58	11.72	0.00	-15.10	4.34	-0.10	8.40	0.00	-3.85	-16.34
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.47	0.45	0.40	0.39	0.40	0.39	0.00	0.00	0.34	0.33	0.31
Accounts Receivable Turnover	10.87	12.19	10.17	9.90	11.52	13.82	0.00	0.00	10.86	13.19	9.84
Inventory Turnover	5.61	5.80	5.31	5.50	5.11	6.00	0.00	0.00	4.85	5.59	5.12
Fixed Asset Turnover	4.04	3.96	3.90	3.72	3.64	3.61	0.00	0.00	3.35	3.04	3.32
Accounts Payable Turnover	8.44	9.98	7.45	13.22	9.96	9.60	0.00	0.00	8.52	8.83	9.37
Days Sales Outstanding (DSO)	33.58	29.94	35.90	36.87	31.68	26.40	0.00	0.00	33.60	27.68	37.10
Days Inventory Outstanding (DIO)	65.11	62.96	68.69	66.38	71.46	60.80	0.00	0.00	75.20	65.27	71.30
Days Payable Outstanding (DPO)	43.25	36.58	48.97	27.61	36.65	38.04	0.00	0.00	42.84	41.35	38.96
Cash Conversion Cycle (CCC)	55.44	56.33	55.63	75.64	66.49	49.17	0.00	0.00	65.95	51.60	69.44
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	4,102	4,092	4,921	4,980	5,009	4,893	0.00	0.00	4,918	4,830	4,830
Invested Capital Turnover	0.62	0.61	1.09	1.05	0.51	0.51	0.00	0.00	0.45	0.43	0.43
Increase / (Decrease) in Invested Capital	-906	-801	4,921	4,980	90	63	-4,830	-4,830	115	0.00	226
Enterprise Value (EV)	9,747	12,089	14,297	9,584	14,365	15,127	0.00	0.00	13,882	10,584	7,536
Market Capitalization	8,041	10,399	12,587	7,796	12,489	13,379	12,325	16,938	12,085	8,797	5,749
Book Value per Share	$12.90	$12.98	$17.38	$17.30	$17.18	$17.39	$0.00	$0.00	$17.51	$17.13	$17.20
Tangible Book Value per Share	($5.16)	($5.26)	($5.53)	($5.52)	($6.04)	($6.15)	$0.00	$0.00	($6.50)	($7.09)	($7.12)
Total Capital	4,888	5,130	5,942	5,927	5,661	5,671	0.00	0.00	5,653	5,462	5,462
Total Debt	2,491	2,727	2,731	2,735	2,528	2,525	0.00	0.00	2,531	2,419	2,419
Total Long-Term Debt	2,491	2,478	2,482	2,486	2,229	2,475	0.00	0.00	2,481	2,419	2,419
Net Debt	1,705	1,689	1,710	1,788	1,876	1,748	0.00	0.00	1,797	1,786	1,786
Capital Expenditures (CapEx)	31	81	26	36	38	35	25	35	29	73	45
Debt-free, Cash-free Net Working Capital (DFCFNWC)	82	50	37	86	82	-48	0.00	0.00	-13	-63	-63
Debt-free Net Working Capital (DFNWC)	868	1,088	1,058	1,033	734	730	0.00	0.00	722	570	570
Net Working Capital (NWC)	868	839	809	784	435	680	0.00	0.00	672	570	570
Net Nonoperating Expense (NNE)	34	251	11	-2.57	36	2.28	4.42	27	20	45	52
Net Nonoperating Obligations (NNO)	1,705	1,689	1,710	1,788	1,876	1,748	0.00	0.00	1,797	1,786	1,786
Total Depreciation and Amortization (D&A)	54	53	55	53	54	54	52	50	50	49	49
Debt-free, Cash-free Net Working Capital to Revenue	2.89%	1.83%	1.39%	3.29%	3.23%	-1.92%	0.00%	0.00%	-0.58%	-3.00%	-3.12%
Debt-free Net Working Capital to Revenue	30.69%	39.45%	39.32%	39.54%	28.96%	29.19%	0.00%	0.00%	32.80%	27.32%	28.40%
Net Working Capital to Revenue	30.69%	30.42%	30.07%	30.01%	17.17%	27.19%	0.00%	0.00%	30.53%	27.32%	28.40%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.54)	($4.69)	($0.21)	($0.09)	($0.60)	($0.26)	$0.00	$0.00	$0.00	($0.72)	($0.84)
Adjusted Weighted Average Basic Shares Outstanding	186.81M	184.20M	184.80M	184.31M	182.35M	180.14M	0.00	0.00	0.00	176.35M	177.00M
Adjusted Diluted Earnings per Share	($0.54)	$0.00	($0.21)	($0.09)	$0.00	$0.00	$0.00	$0.00	$0.00	($0.72)	($0.84)
Adjusted Weighted Average Diluted Shares Outstanding	186.81M	184.20M	184.80M	184.31M	184.53M	180.14M	0.00	0.00	0.00	176.35M	177.00M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	188.64M	185.76M	185.08M	184.77M	184.53M	181.53M	0.00	0.00	0.00	0.00	177.68M
Normalized Net Operating Profit after Tax (NOPAT)	-63	-27	-14	-13	-72	-47	5.21	-53	-54	-81	-92
Normalized NOPAT Margin	-8.89%	-3.75%	-2.05%	-1.81%	-11.23%	-7.34%	0.83%	-8.59%	-8.95%	-14.61%	-17.68%
Pre Tax Income Margin	-14.29%	-122.78%	-5.28%	-2.05%	-17.01%	-7.79%	0.17%	-12.85%	-12.03%	-23.50%	-29.04%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-9.12	-91.51	-4.10	0.00	-12.65	-8.63	0.87	-9.84	0.00	-23.02	-28.01
NOPAT to Interest Expense	-6.74	-64.05	-2.87	0.00	-9.40	-6.04	0.66	-6.89	0.00	-15.38	-18.46
EBIT Less CapEx to Interest Expense	-12.25	-100.00	-6.82	0.00	-17.39	-13.13	-2.33	-14.28	0.00	-36.49	-36.54
NOPAT Less CapEx to Interest Expense	-9.86	-72.54	-5.59	0.00	-14.14	-10.54	-2.54	-11.33	0.00	-28.85	-26.99
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Exact Sciences' Financials

When does Exact Sciences's financial year end?

According to the most recent income statement we have on file, Exact Sciences' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Exact Sciences' net income changed over the last 9 years?

Exact Sciences' net income appears to be on an upward trend, with a most recent value of -$1.03 billion in 2024, rising from -$157.80 million in 2015. The previous period was -$204.15 million in 2023. See where experts think Exact Sciences is headed by visiting Exact Sciences' forecast page.

What is Exact Sciences's operating income?

Exact Sciences's total operating income in 2024 was -$1.05 billion, based on the following breakdown:

Total Gross Profit: $1.92 billion
Total Operating Expenses: $2.97 billion

How has Exact Sciences revenue changed over the last 9 years?

Over the last 9 years, Exact Sciences' total revenue changed from $39.44 million in 2015 to $2.76 billion in 2024, a change of 6,895.6%.

How much debt does Exact Sciences have?

Exact Sciences' total liabilities were at $3.53 billion at the end of 2024, a 6.0% increase from 2023, and a 9,384.8% increase since 2015.

How much cash does Exact Sciences have?

In the past 9 years, Exact Sciences' cash and equivalents has ranged from $41.14 million in 2015 to $1.49 billion in 2020, and is currently $600.89 million as of their latest financial filing in 2024.

How has Exact Sciences' book value per share changed over the last 9 years?

Over the last 9 years, Exact Sciences' book value per share changed from 3.39 in 2015 to 12.98 in 2024, a change of 282.6%.

Related Companies

This page (NASDAQ:EXAS) was last updated on 5/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Exact Sciences (EXAS) Financials

Frequently Asked Questions About Exact Sciences' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Exact Sciences (EXAS) Financials

Annual Income Statements for Exact Sciences

Quarterly Income Statements for Exact Sciences

Annual Cash Flow Statements for Exact Sciences

Quarterly Cash Flow Statements for Exact Sciences

Annual Balance Sheets for Exact Sciences

Quarterly Balance Sheets for Exact Sciences

Annual Metrics And Ratios for Exact Sciences

Quarterly Metrics And Ratios for Exact Sciences

Frequently Asked Questions About Exact Sciences' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools